Glioma Diagnosis and Treatment

This study identifies RBBP4 as a critical regulator of cell cycle progression in TMZ-resistant glioblastoma through CRISPR screens and functional analyses.

This study identifies two epigenetically-defined spatial niches in glioblastoma that influence cell state plasticity through local and long-range molecular signals.

The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.

This study profiles hypoxic glioblastoma stem cells using multi-omics to reveal distinct subpopulations with unique epigenetic and CNV profiles.

This study uses a 3D hydrogel model of the brain perivascular niche to investigate how radiation dosage and delivery rate affect niche properties in vitro.

This study identifies the SPP1-CD44 axis as an immunosuppressive pathway in pediatric high-grade glioma and develops an antibody to disrupt it using single-cell and structural bioinformatics.

The paper identifies gene regulatory networks linked to GABA signaling in glioblastoma using multi-omics data and machine learning, showing GABA signaling promotes tumor growth through non-synaptic mechanisms.

The paper integrates spatial multi-omics data from diffuse gliomas to identify locoregional metabolomic regulators linked to glioma growth and treatment resistance.

This study characterizes immune cell composition in immunocompetent and immunodeficient mice with orthotopic brain tumors, finding significant differences in immune cell frequencies across tissues and after irradiation.

The paper identifies metabolic vulnerabilities in TMZ-resistant glioblastoma cells, showing that iron reduction enhances the efficacy of TMZ through mechanisms involving Hif1, autophagy, and ROS.

This study identifies a synergistic combination of FAK and MEK inhibitors that effectively targets glioblastoma heterogeneity and improves therapeutic outcomes.

This paper introduces GBM-cRegMap, a resource that maps transcriptomic data to a coregulatory network, revealing GBM heterogeneity and identifying key regulators like NKX2.5 involved in TMZ resistance.

This study shows that CARM1 loss in GSCs disrupts developmental programming, shifts lineage towards radial glia, and creates a dependency on NGFR/NTRK signaling, making them vulnerable to NTRK inhibitors.

The paper develops a novel urea-based compound, MXC-017, that crosses the blood-brain barrier, targets glioma stem cells, and improves survival in GBM models when combined with radiation.

This study identifies EP300 as a regulator of the Injury-Response state in Glioblastoma Stem Cells through a CRISPR-Cas9 screen, showing its role in maintaining IR state features and tumor aggressiveness.

This study uses single-cell transcriptomics to analyze GBM tumor microenvironment, identifying immunosuppressive macrophage subtypes and exhausted NK cells, suggesting therapeutic targets.

This study identifies six immunogenic peptides in diffuse midline glioma (DMG) linked to the H3K27M mutation, offering potential targets for T cell-based immunotherapy.

This paper optimizes an in utero electroporation method to model DIPG in mice by expressing mutant oncogenes in neural progenitors, resulting in tumors with DIPG molecular features.

The paper shows BRCA1 correlates with proliferation in human neural progenitor cells and medulloblastoma, particularly in Group 3 and 4 tumors, and is linked to worse prognosis.

This paper introduces a gel-top culture model that replicates mesenchymal features of glioblastoma cells and identifies CK2 as a potential therapeutic target.

This paper evaluates the safety and efficacy of SHP1705, a CRY2 activator, in preclinical models and Phase I trials, showing improved efficacy against GBM stem cells and synergistic effects with a REV-ERB agonist.

This paper shows that combining ONC201 or ONC206 with temozolomide and radiotherapy significantly extends survival in a GBM mouse model compared to single treatments.

The paper examines TIL expansion in glioblastoma by analyzing spatial organization and myeloid context, finding that TIL+ tumors have distinct immune interactions and vascular niches.

This study identifies HDAC inhibitors as enhancers of TAM phagocytosis and synergistic partners for immunotherapy in GBM through high-throughput screening.

The paper uses multiplexed immunofluorescence and AI models to analyze the tumor microenvironment of diffuse midline glioma and predict antigens from H&E staining.

This paper introduces GlioTrace, an ex vivo imaging and AI framework to track glioblastoma invasion dynamics in patient-derived brain slices, revealing patient-specific invasion patterns and drug responses.

The paper investigates the role of AIMP proteins in glioma angiogenesis and their predictive value for anti-angiogenic therapy response using multi-omics and single-cell data.

This paper shows SUV39H1 is critical for maintaining glioblastoma stem cell properties and progression, and targeting it enhances chemotherapy effectiveness.